Evidence map›Paper›PMID 35073905›Full record

ArticleReproductive biology and endocrinology : RB&E2022

Recombinant anti-Müllerian hormone in the maturation medium improves the in vitro maturation of human immature (GV) oocytes after controlled ovarian hormonal stimulation.

Jure Bedenk, Tadeja Režen, Taja Železnik Ramuta, Nina Jančar, Eda Vrtačnik Bokal, Ksenija Geršak, Irma Virant Klun

Abstract read
In one paragraph

Article in Reproductive biology and endocrinology : RB&E, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Effect of Anti-Müllerian Hormone on Oocytes In Vitro Maturation in Sheep.International journal of molecular sciences · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jure BedenkClinical Research Centre, University Medical Centre Ljubljana, 1000, Ljubljana, Slovenia. jure.bedenk@kclj.si.ORCID http://orcid.org/0000-0002-4033-2355
Tadeja ReženInstitute of Biochemistry and Molecular Genetics, Centre for Functional Genomics and Bio-Chips, Faculty of Medicine, University of Ljubljana, 1000, Ljubljana, Slovenia.
Taja Železnik RamutaInstitute of Cell Biology, Faculty of Medicine, University of Ljubljana, 1000, Ljubljana, Slovenia.
Nina JančarDepartment of Gynaecology and Obstetrics, University Medical Centre Ljubljana, 1000, Ljubljana, Slovenia.
Eda Vrtačnik BokalDepartment of Gynaecology and Obstetrics, University Medical Centre Ljubljana, 1000, Ljubljana, Slovenia.
Ksenija GeršakFaculty of Medicine, University of Ljubljana, 1000, Ljubljana, Slovenia.
Irma Virant KlunClinical Research Centre, University Medical Centre Ljubljana, 1000, Ljubljana, Slovenia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn vitro maturation (IVM) of oocytes is a laboratory method that allows the maturation of immature (GV) oocytes retrieved from patients enrolled in the in vitro fertilization (IVF) programme. However, this method is still sparsely researched and used in clinical practice, leading to suboptimal clinical results. Anti-Müllerian hormone (AMH) is an important hormone with known effects on human ovaries, especially on follicles (follicular cells) during folliculogenesis. In contrast, the effect of AMH on the human oocyte itself is unknown. Therefore, we wanted to determine whether human oocytes express AMH receptor 2 (AMHR2) for this hormone. Recombinant AMH was added to the IVM medium to determine whether it affected oocyte maturation.

methodsIn total, 247 human oocytes (171 immature and 76 mature) were collected from patients enrolled in the intracytoplasmic sperm injection (ICSI) programme who were aged 20 to 43 years and underwent a short antagonist protocol of ovarian stimulation. The expression of AMHR2 protein and AMHR2 gene was analysed in immature and mature oocytes. Additionally, maturation of GV oocytes was performed in vitro in different maturation media with or without added AMH to evaluate the effect of AMH on the oocyte maturation rate.

resultsImmunocytochemistry and confocal microscopy revealed that AMHR2 protein is expressed in both immature and mature human oocytes. AMHR2 was expressed in a spotted pattern throughout the whole oocyte. The IVM procedure revealed that AMH in maturation medium improved GV oocyte maturation in vitro, as all oocytes were successfully matured in maturation medium containing recombinant AMH only. Furthermore, antagonism between AMH and follicle-stimulating hormone (FSH) during the maturation process was observed, with fewer oocytes maturing when both AMH and FSH were added to the maturation medium. Finally, AMHR2 gene expression was found in immature and in vitro matured oocytes but absent in mature oocytes.

conclusionsThe positive AMHR2 protein and AMHR2 gene expression in human oocytes shows that AMH could directly act on human oocytes. This was further functionally confirmed by the IVM procedure. These findings suggest the potential clinical application of recombinant AMH to improve IVM of human oocytes in the future.

Indexed as

AdultAnti-Mullerian HormoneCells, CulturedCulture MediaFemaleGene ExpressionHumansIn Vitro Oocyte Maturation TechniquesOocytesOogenesisOvulation InductionReceptors, PeptideReceptors, Transforming Growth Factor betaRecombinant ProteinsYoung AdultAnti-Mullerian Hormoneanti-Mullerian hormone receptorCulture MediaReceptors, PeptideReceptors, Transforming Growth Factor betaRecombinant ProteinsAnti-Müllerian hormoneAnti-Müllerian hormone receptor 2Confocal microscopyHuman oocyteImmunocytochemistryIn vitro maturationRT–qPCR

Identifiers

PMID35073905
PMCPMC8785574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.